Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
August 28, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis
August 13, 2018 08:30 ET
|
Arbutus Biopharma Corporation
ONPATTRO Approval Triggers Royalty to Arbutus Clinically Validated LNP Technology Now in the Hands of Genevant to Develop RNA-based Products WARMINSTER, Pa., Aug. 13, 2018 (GLOBE NEWSWIRE) --...
Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
August 02, 2018 16:00 ET
|
Arbutus Biopharma Corporation
- Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated - Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half...
(iXBRL) Inline XBRL Updates
June 29, 2018 23:00 ET
|
M2 Compliance
LOS ANGELES, CA, June 29, 2018 (GLOBE NEWSWIRE) -- M2 Compliance ("M2"), Yesterday (6/28/18), the SEC voted to adopt rules mandating the use of Inline XBRL (eXtensible Business Reporting Language)...
Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer
June 07, 2018 17:44 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., June 07, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
M2 Compliance® to Sponsor the 8th Annual LD Micro Invitational Event
June 01, 2018 07:00 ET
|
M2 Compliance
LOS ANGELES, CA, June 01, 2018 (GLOBE NEWSWIRE) -- M2 Compliance® ("M2"), www.m2compliance.com, a world-leading filing agent registered with the Securities and Exchange Commission and full-service...
Arbutus Announces Corporate Update and First Quarter 2018 Financial Results
May 03, 2018 16:00 ET
|
Arbutus Biopharma Corporation
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA...
Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results
April 30, 2018 09:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
April 12, 2018 12:00 ET
|
Arbutus Biopharma Corporation
Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy ResultsSubcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose VANCOUVER, British Columbia...
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
April 11, 2018 17:24 ET
|
Arbutus Biopharma Corporation
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platformsGenevant will be led by...